We are pleased to announce that Medicilon will attend the EFMC-ISMC 2026 – one of the premier biennial events in medicinal chemistry and drug discovery, organized by the European Federation for Medicinal Chemistry (EFMC). This international symposium brings together around 1,000 participants from both industry and academia, featuring plenary sessions and parallel tracks across Chemical Biology, Medicinal Chemistry, and Enabling Technologies.
Where: Congress Centre Basel, Switzerland – Medicilon Booth #46
Date: September 6-10, 2026
We look forward to connecting with you in Basel and showcasing our integrated drug R&D platforms – from early discovery through CMC development and IND-enabling studies – all under one roof.
Meet our team on site:
- Dr. Paul van Stralen – VP Strategic Collaborations EMEA
- Dr. Wei Hu – Director BD Europe
What We Highlight at EFMC-ISMC 2026 – Integrated Drug Discovery & Development
With 690+ IND approvals supported worldwide (FDA, NMPA, EMA, TGA, MFDS, PMDA) and over 22 years of industry experience, Medicilon provides a full spectrum of services to accelerate your program from target to IND.
Drug Discovery Services
- Medicinal Chemistry – Focused library construction, activity screening, hit identification, lead generation, SAR development, lead optimization, PCC selection
- Custom Synthesis – Special reagents/intermediates synthesis, reference/standard synthesis, impurities/metabolites synthesis, stable isotope internal standards
- Process Chemistry – Reference scale-up, hundred-gram to kilogram synthesis, lead/PCC compound scale-up for animal studies, early-stage process development
- Biology Services – In vitro assays, high-throughput screening, antibody discovery, recombinant protein expression
AIDD Drug Discovery Platform
We have built a comprehensive AI-driven discovery platform that covers:
- Small Molecules – Generative design, structure/ligand-based virtual screening, ADMET prediction
- PROTAC – Novel linker generation via diffusion models, screening for targeted protein degradation candidates
- Peptide – Protein-peptide complex structure prediction, binding affinity scoring, de novo peptide design
- siRNA/ASO – AI-driven design optimizing mRNA accessibility, thermodynamic stability, and off-target prediction
- ADMET/PK Modeling – In-house MADDIE models for multi-species PK prediction and comprehensive ADMET profiling
CMC Development & Formulation
From IND-enabling materials to commercial-ready formulations, our CMC platform covers:
- API Development – Process R&D from gram-scale to multi-ton GMP manufacturing
- QC & Characterization – Analytical method development, impurity studies, crystal form/PSD analysis, ICH stability testing
- Formulation Development – Solids, semi-solids, liquids, and specialized forms (inhalation, sustained-release, solid dispersion, nanoparticles)
- GMP Manufacturing – Fully compliant GMP workshops for solid, semi-solid, and inhalation formulations, with in-house analytical release testing
Beyond the Booth – Let’s Talk About Your Full Program
While our booth showcases our full integrated capabilities, we know every program is different. Whether you are exploring a new modality, optimizing a lead series, or preparing for IND-enabling studies, we would welcome the opportunity to understand your specific needs and discuss how we can support your journey.
Come talk to the Medicilon team – we would be happy to explore how our integrated model, technology platforms, and regulatory track record can help accelerate your program from discovery to clinic.
See you in Basel!
